Plenary Session 4205

MDS Keynote Lecture and Clinical Breakthroughs

Wednesday, October 8, 2025
8:00 - 09:30 | Ballroom

Chairs:

Manju Kurian, United Kingdom

Presenters:

Clinical Breakthrough Presentation - Safety, tolerability, pharmacokinetics and pharmacodynamics of VTX3232, a CNS-penetrant NRLP3 inhibitor, in participants with early-stage Parkinson’s disease
Mark Forman, USA

Clinical Breakthrough Presentation - Phase 1/2a clinical trial of hESC-derived dopaminergic progenitors in Parkinson’s disease
Han Kyu Na, South Korea

Clinical Breakthrough Presentation - Risvodetinib treatment drives clearance of alpha-synuclein pathology in untreated Parkinson’s disease: a randomized Phase 2 Trial
Milton Werner, USA

MDS Keynote Lecture
Sergiu Pasca, USA

CSPC Liaisons:

Maria Stamelou, Greece

Recommended Audience

Clinician / General Neurology
Fellow / Resident / Student
Health Professional (non-physician)
Industry
Researcher / Basic Science

Education Level

Advanced / Expert
Beginner / Foundational
Intermediate / Experienced

Focus

Undefined